Glow LifeTech (GLOW) AI Stock Analysis

• Market Cap: C$7.90M
• Dividend Yield: N/A
• Average Volume (3M): 330.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: 2733.38%
• EPS Growth: 34.80%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 62
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 121,511,960
• 10 Day Avg. Volume: 581,263
• 30 Day Avg. Volume: 330,056
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 16.44
• Price to Cash Flow (P/CF): -13.60
• P/FCF Ratio: 109.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Glow LifeTech's overall stock score is primarily hindered by its financial performance, marked by persistent losses and cash flow issues. While technical indicators show positive momentum, valuation concerns due to negative earnings weigh on the score. Recent corporate developments offer potential strategic benefits, but financial and profitability improvements are crucial for a higher assessment.

Glow LifeTech Business Overview & Revenue Model

Company Description

Glow LifeTech (GLOW) is a biotechnology company focused on enhancing the bioavailability of active ingredients through its proprietary delivery systems. The company operates in the health, wellness, and pharmaceutical sectors, offering solutions that improve the absorption and efficacy of nutraceuticals, cannabinoids, and other bioactive compounds. Glow LifeTech aims to transform how consumers experience health supplements and medical therapies by providing more effective and efficient delivery mechanisms.

How the Company Makes Money

Glow LifeTech generates revenue primarily through the commercialization of its advanced delivery technology platforms. The company licenses its proprietary systems to nutraceutical and pharmaceutical companies, allowing them to incorporate these technologies into their products for improved bioavailability. Additionally, Glow LifeTech may engage in direct sales of its own branded products that utilize its technology. Significant partnerships with industry leaders and research institutions further contribute to its earnings by expanding market reach and fostering innovation. The company's revenue streams are supported by ongoing research and development efforts and potential collaborations focused on new applications of its delivery systems.

Glow LifeTech Financial Statement Overview

Summary

Glow LifeTech faces considerable financial challenges, characterized by persistent losses and cash flow difficulties. Although revenue has increased recently, profitability and cash management are critical areas requiring significant improvement to ensure long-term viability.

Income Statement

The company exhibits a challenging financial trajectory with a significant net loss and negative profit margins. Despite a substantial increase in revenue over the TTM, the negative EBIT and EBITDA margins indicate ongoing operational inefficiencies.

Balance Sheet

The balance sheet reflects high leverage, with a concerning debt-to-equity ratio due to negative equity in previous periods. While there is some improvement in equity, the company remains highly leveraged relative to its assets.

Cash Flow

Cash flow analysis reveals a negative free cash flow and high operating cash outflows, highlighting cash management issues. The company's financing activities have temporarily bolstered cash reserves, but sustainability remains questionable.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
552.31K	43.93K	0.00	0.00	0.00	0.00
	Gross Profit
30.27K	10.05K	-588.65K	-43.39K	0.00	0.00
	EBIT
-1.03M	-1.64M	-2.30M	-5.28M	-153.48K	-182.77K
	EBITDA
-996.19K	-1.26M	-1.71M	-4.59M	-153.48K	740.02K
	Net Income Common Stockholders
-1.47M	-1.65M	-2.24M	-11.32M	-153.48K	-56.13K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
20.45K	34.00	24.09K	746.02K	1.80K	20.45K
	Total Assets
20.56K	1.91M	2.31M	3.76M	2.60K	20.56K
	Total Debt
6.40K	171.75K	641.14K	39.93K	6.40K	6.40K
	Net Debt
-14.05K	171.71K	617.05K	-706.09K	4.60K	-14.05K
	Total Liabilities
180.05K	2.35M	1.14M	328.03K	315.57K	180.05K
	Stockholders Equity
-159.49K	-433.12K	1.16M	3.44M	-312.97K	-159.49K
Cash Flow		Free Cash Flow
-1.18M	-490.86K	-1.36M	-3.62M	-18.65K	16.63K
	Operating Cash Flow
-1.18M	-417.26K	-1.30M	-3.18M	-18.65K	16.63K
	Investing Cash Flow
11.55K	-60.91K	-28.51K	-541.41K	―	―
	Financing Cash Flow
2.01M	445.01K	488.85K	4.59M	―	―

Glow LifeTech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GLOW, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and above the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.26 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GLOW.

Glow LifeTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRON	68 Neutral	C$979.28M	17.52	3.80%	―	35.87%	―
TRUL	49 Neutral	$1.04B	―	-12.12%	―	6.27%	67.62%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
ACB	47 Neutral	C$344.12M	27.35	4.78%	―	16.39%	-98.10%
GLOW	41 Neutral	C$7.90M	―	-428.71%	―	2733.38%	34.80%
WEED	36 Underperform	$240.85M	―	-84.50%	―	-16.27%	76.17%

Glow LifeTech Corporate Events

Glow LifeTech Strengthens Board with New Appointment

Glow LifeTech Corp. has appointed David Côté, a seasoned leader in the cannabis retail industry, to its Board of Directors. Côté’s experience in scaling retail operations is expected to aid Glow’s expansion in the Canadian cannabis retail market, aligning with the company’s growth strategy. The appointment is accompanied by a grant of stock options, and coincides with internal changes where James Van Staveren steps down from the Audit Committee and Corporate Secretary roles, with Côté and CFO Josh Bald taking over those positions, respectively.

Glow LifeTech Expands MOD™ Drops to New Brunswick, Entering Atlantic Canada

Glow LifeTech has announced its expansion into the New Brunswick market with its MOD™ drops, marking its first entry into Atlantic Canada. This strategic move follows a successful year in Ontario and aligns with the company’s growth strategy to broaden its footprint across Canada, leveraging its proprietary technology to capture new market opportunities and drive growth.

Glow Lifetech Issues Stock Options to Team

Glow Lifetech Corp has granted 3,650,000 stock options to its officers and consultants, offering an opportunity for increased insider participation. The options come with a five-year exercise period, highlighting the company’s commitment to incentivizing its team amid its innovative focus on nutraceutical and cannabinoid-based products.

Glow Lifetech Finalizes Share Issuance and Debt Settlement

Glow Lifetech Corp. plans to issue 10 million shares to finalize its acquisition of Swiss Pharma, strengthening their strategic partnership in the cannabis and natural health sectors. Additionally, Glow intends to settle $510,470.44 in outstanding debt by issuing over 8 million shares, aiming to preserve cash for working capital.

Glow LifeTech Reports Strong Q3 2024 Results

Glow LifeTech Corp. reported a strong Q3 2024 with a 49% increase in revenue and 73% gross margins, reflecting its commitment to profitability and growth. The company improved its financial health through significant financing and debt settlement, enabling strategic investments. Glow also expanded its retail footprint in Ontario, positioning itself as a leader in the oils category.

Glow Lifetech Completes Funding and Debt Settlement

Glow Lifetech Corp. successfully completed a $900,000 private placement and settled $591,000 in debt by issuing shares, aimed at preserving cash for working capital. Insiders participated in the transaction, which was classified as a related party transaction, and Nova Capital Corp. increased its stake in the company. This strategic move reflects Glow Lifetech’s efforts to strengthen its financial standing.